Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 Results: Total...

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (Scott+Scott), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (Fulgent) (NASDAQ: FLGT) for ...

NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of long-term stockholders following a class action complaint that was filed against ...

PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which itself is wholly-...

Piper Sandler downgraded shares of Fulgent Genetics (NASDAQ:FLGT Get Rating) from an overweight rating to a neutral rating in a research note issued to investors on Thursday morning, MarketBeat.com reports. They currently have $40.00 price target on the stock, down from their prior price ...